BerGenBio ASA (BRRGF) has released an update.
BerGenBio ASA has reported positive preliminary safety data from the Phase 1b BGBC016 study, demonstrating that its AXL inhibitor, bemcentinib, is well-tolerated when combined with standard therapies for first-line treatment of advanced Non-Small Cell Lung Cancer. The study showed no new safety concerns and confirmed adequate plasma exposure of the drug, which aligns with previous positive results, thus supporting further clinical development. The company, which specializes in developing drugs for severe unmet medical needs, looks forward to advancing to the next trial phase, focusing on patients with STK11 gene mutations.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.
